PL 9588
Alternative Names: PL-9588Latest Information Update: 14 May 2023
At a glance
- Originator Palatin Technologies
- Class Eye disorder therapies; Peptides
- Mechanism of Action Melanocortin type 1 receptor agonists; Melanocortin type 5 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Glaucoma